Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression
NCT06501976Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in Small Cell Lung Cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Dec 2025; status: active, not recruiting.
02
Drugs
lurbinectedin
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT06501976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501976.